Human partial reprogramming eye study for glaucoma and NAION completes enrollment
A first-in-human study testing partial cellular reprogramming in the eye has completed enrollment. Safety data are expected in Q4 2026, and no efficacy results have been released yet.
Source: Partial reprogramming eye trial completes enrollment (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
According to the article, the first human study of partial reprogramming, using OSK factors, has completed enrollment of participants. The research aims to test this approach in glaucoma and in non-arteritic anterior ischemic optic neuropathy (NAION). Safety data are expected in the fourth quarter of 2026. The author claims this would be the first human attempt at age reversal. No efficacy results have been released yet.
Partial reprogramming is a line of research that tries to reverse signs of aging in cells without erasing their identity. So far, these techniques have been studied mainly in animals and in laboratory cells, and the article does not report results in people. Starting human trials is an important step, but safety and benefit still need to be shown in larger and longer studies. Rejuvenation claims should be read as expectations, not as achievements.
What it means
What this means: research has moved into testing in people with glaucoma and NAION, conditions that affect the optic nerve. What is still unknown: whether the approach is safe over the long term and whether it offers any benefit for vision.
How to read it with care
This result does not replace a consultation. Anyone with glaucoma or vision problems should see an eye doctor. Any change in diet, supplements or treatment should be discussed with a doctor or another qualified professional.